PCR Press Releases

The PCR Press Office welcome enquiries about its Courses, initiatives and activities in interventional cardiovascular medicine.

For any press-related inquiries about EuroPCR:

Contact us

 

About PCR

  • Find out more about PCR here.
  • Join the conversation all year long with @PCRonline on Twitter: not only do we enjoy speaking to you, we also love hearing from you!
  • Use the #EuroPCR hashtag to tweet about the World-Leading Course in interventional cardiovascular medicine
Filter By

40 results

In Person in Paris and online EuroPCR 2022 celebrates the best of both worlds

09 May 2022

EuroPCR is celebrating being back home in Paris, in-person, for the first time in 3 years. This year’s international Course will see both a complete on-site programme and a full digital experience, bringing the community together to share and learn.

In Person in Paris and online EuroPCR 2022 celebrates the best of both worlds

EuroPCR 2021 - Unprecedented global outreach and online interactivity during an innovative livestreamed edition

25 May 2021

Paris, France. 21 May 2021.  Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

EuroPCR 2021

A new meta-analysis supports elective revascularization and medical therapy for reducing cardiac death

18 May 2021

The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic coronary syndromes and moderate to severe ischemia at a mean of 3.2 years. However, the cumulative difference in the estimates of cardiac death between the invasive and conservative...

A new meta-analysis supports elective revascularization and medical therapy for reducing cardiac death

One-year results from the FUTURE-II trial

18 May 2021

A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS vs. metallic drug-eluting stent in terms of the so-called vascular restoration therapy with recovery of vasomotion...

One-year results from the FUTURE-II trial

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

18 May 2021

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

18 May 2021

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Authors :

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

EBC MAIN trial results – what is new and what will change in left main stenting?

18 May 2021

The European Bifurcation Club Left Main (EBC MAIN) trial addressed the issue of provisional single stent versus upfront double stenting in 467 patients with true bifurcation distal left main disease. 

So far, only one other randomized trial, DKCRUSH-V (n=482), has addressed the same research question, showing better...

EBC MAIN trial results – what is new and what will change in left main stenting?

Cool AMI EU pivotal trial- final results after trial discontinuation following ad interim analysis

18 May 2021

Results of the interim analyses performed after 12 months in the first 111 patients enrolled in phase II Cool AMI trial evaluating safety and effectiveness of systemic therapeutic hypothermia as an adjunctive therapy in anterior STEMI undergoing PCI as compared to PCI only. Analyses showed significant...

Cool AMI EU pivotal trial- final results after trial discontinuation following ad interim analysis

2021 Ethica Award: Dr. Marie-Claude Morice to receive the 2021 Andreas Grüntzig Ethica Award

17 May 2021

Paris, France, 10 May 2021 - EuroPCR, taking place online from 18 to 20 May 2021, will be an opportunity for the interventional cardiovascular community to come together and benefit from interactive training with their peers. At this year’s web-based event, Dr. Marie-Claude Morice will be presented with the Andreas...

2021 Ethica Award: Dr. Marie-Claude Morice to receive the 2021 Andreas Grüntzig Ethica Award

We CARE: a joint initiative by PCR and Stent – Save a Life!

07 May 2021

Paris, France. Since the start of the COVID-19 pandemic, patients have been consistently deprived of timely cardiovascular treatment. This is due in part to measures taken in response to the sanitary crisis, but it is also due to patients' own unwillingness to seek medical help, even...

We CARE: a joint initiative by PCR and Stent – Save a Life!